𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @mmammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more. Full video: biotechtv.com/post/parabilis…

Zolucatetide, A Modified Peptide Polymacrocycle from Parabilis is the First β-catenin/TCF4 PPI Inhibitor to Reach the Clinic | drughunters.com/4gsz87A Brian White of Parabilis Medicines presented the discovery story of zolucatetide (FOG-001), a β-catenin/TCF4 interaction inhibitor currently in a Ph. 1/2 trial for advanced solid tumors, at the ACS Fall 2025 meeting. The starting point for this stapled peptide was discovered using the company’s Helicon™ platform for identifying hyperstabilized α-helical peptides (stay tuned for Drug Hunter’s upcoming modality brief on stapled peptides). Zolucatetide incorporates multiple backbone cyclizations to enforce helicity, limit solvent-exposed amide hydrogen atoms, and enable cytosolic exposure. This case study will examine the challenges and opportunities that exist in modulating the Wnt/β-catenin pathway and how Parabilis employed their platform to generate the hit compound that led to the first selective inhibitor of the β-catenin/CFT4 PPI to enter human trials. Read it on Drug Hunter: drughunters.com/4gsz87A

FogPharma, Artbio join forces to design a different radiopharma drug biopharmadive.com/news/fogph… by @NedPagliarulo

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few biotechs meet. trib.al/2RlQV67

Tearing up the traditional biotech playbook go.nature.com/4aNnrVS

A question I've always been fascinated by is: how can you access totally new chemical space and mine it with high throughput? How can you discover something new from nothing? In that regard, @RosslerSimon and @NathalieGrob put on a clinic science.org/doi/10.1126/scie…

In a collaboration between @BuchwildGroup & @PenteluteLab, we developed peptide-encoded libraries (PELs) as a new platform for small molecule drug discovery. This work with @NathalieGrob is now out in @ScienceMagazine science.org/doi/10.1126/scie… #ScienceResearch @ChemistryMIT

Amazing work! Congrats!

An update we were all hoping for. ❤️💙

Damar Hamlin is a truly wonderful and special person. He’s made an enormous impact on his community, long before he made the NFL — as you’ll see in the video below. Please pray for Damar and his family. 🙏

Excited to present our @biorxivpreprint on chemical rational design of molecular glue degraders through a covalent handle targeting RNF126! Congrats to @EthanToriki & @JPapatzimas who led work w/@NovartisScience! & thanks to @TheMarkFdn ! biorxiv.org/content/10.1101/…

👀 science.org/doi/10.1126/scie…

Oh my peptide! @RosslerSimon @NathalieGrob with some amazing work here. Can't wait to see where this leads! @PenteluteLab @BuchwildGroup @ChemistryMIT

Excited to represent FogPharma today at the @MIT career fair! Come out and hear about how we are using cutting edge screening technology and AI to tackle historically #undruggable targets #BetaCatenin #UniversalDruggability #DeepLearning #DirectedEvolution #MultiplexedHTS

The just-announced U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization represents a stunning reversal of precedent that inserts government into the personal lives and health care of Americans. nej.md/3Aa5cKe

Please just stop.. unless you are willing to break the filibuster to actually pass sensible gun control measures you might as well just say “thoughts and prayers”

I will never, ever, for the life of me, understand.

Incredibly excited to share our paper ‘Somatic mutation rates scale with lifespan across mammals’ now published @nature. nature.com/articles/s41586-0… An illustrated & updated tweetorial… [1/24]

Wow!

The maestro! @PomplunSeb